Bone marrow transplantation for solid tumors in pediatrics

  • Thomas J. Moss
Part of the Cancer Treatment and Research book series (CTAR, volume 50)

Abstract

There is growing evidence that bone marrow transplantation is an effective means of treating solid tumors in the pediatric age group. Conventional chemoradiotherapy, in which the dose is limited by the degree of bone marrow suppression, does not increase long-term survival for most disseminated neoplasms. Bone marrow transplantation utilizes high-dose chemoradiotherapy without regard to marrow toxicity and may be the treatment of choice for these malignancies.

Keywords

Toxicity Lymphoma Oncol Methotrexate Cyclophosphamide 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Franklin I, Pritchard J. Detection of bone marrow invasion by neuroblastoma is improved by sampling at two sites with both aspirates and trephine biopsies. J Clin Pathol 1983; 36:1215–1218.PubMedCrossRefGoogle Scholar
  2. 2.
    Brunning R, Bloomfield C, McKenna R, Peterson L. Bilateral trephine bone marrow biopsies in lymphoma and other neoplastic diseases. Ann Intern Med 1975; 82:365–6.PubMedGoogle Scholar
  3. 3.
    Hirsch F, Hansen H, Hainau B. Bilateral bone-marrow examinations in small-cell anaplastic carcinoma of the lung. Acta Path Microbiol Scand 1979; 87A:59–62.Google Scholar
  4. 4.
    Moss TJ, Seeger RC, Kindler-Rohrborn A, Marangos PJ, Rajewsky MF, Reynolds, CP. Immunohistologic detection and phenotyping of neuroblastoma cells in bone marrow using cytoplasmic neuron specific enolase and cell surface antigens. Prog Clin Biol Res 1975; 175:367–378.Google Scholar
  5. 5.
    Evans AE, Griffin GC, Tartaglione M, Kennett RH. A method of detecting neuroblastoma in human bone marrow by means of two monoclonal antibodies PI 153/3 and KE2. Hybridoma 1985; 4:289–296.PubMedCrossRefGoogle Scholar
  6. 6.
    Cheung NV, Van Hoff DD, Strandjord SE, Coccia PF. Detection of neuroblastoma cells in bone marrow using GD2 specific monoclonal antibodies. J Clin Oncol 1986; 4:363–369.PubMedGoogle Scholar
  7. 7.
    Redding WH, Monaghan P, Imrie SF, Ormerod MG, Gazet J, Coombes RC, Clink FM, Dearnaley DP, Sloane JP, Powles TJ, Neville Am. Detection of micrometastases in patients with primary breast cancer. Lancet 1983; 2:1271–1273.PubMedCrossRefGoogle Scholar
  8. 8.
    Stahel RA, Mabry M, Skarkin AT, Speak J, Bernai SD. Detection of bone marrow metastasis in small-cell lung cancer by monoclonal antibody. J Clin Oncol 1985; 3:455–461.PubMedGoogle Scholar
  9. 9.
    Moss TJ, Reynolds, CP, Reisfeld RA, Sather H, Hammond D, Seeger RC. Sensitive immunohistologic detection of neuroblastoma cells in bone marrow using monoclonal antibodies. Clin Res 1986; 35:230a.Google Scholar
  10. 10.
    Cecchetto G, Luzzatto C, Carli M, Guglieimi M, Zanesco L. The role of Surgery in non-localized neuroblastoma. Analysis of 59 cases. Tumori 1983; 69:327–329.PubMedGoogle Scholar
  11. 11.
    Grosfeld JL, Ballantine TVN, Baehner RL. Experience with ‘second-look’ operations in pediatric solid tumors. J Ped Surg 1978; 13:275–280.CrossRefGoogle Scholar
  12. 12.
    Grosfeld JL, Schatzlein M, Ballantine TVN, Weetman RM, Baehner RL. Metastatic neuroblastoma: Factors influencing survival. J Ped Surg 1978; 13:59–65.CrossRefGoogle Scholar
  13. 13.
    Smith EI, Krous HF, Tunell WP, Hitch DC. The impact of chemotherapy and radiation therapy on secondary operations for neuroblastoma. Ann Surg 1980; 191:561–568.PubMedCrossRefGoogle Scholar
  14. 14.
    Moss TJ, Fonkalsrud E, Feig SA, Lenarsky C, Selch M, Wells M, Seegar RC. Delayed surgery and bone marrow transplantation for widespread neuroblastoma. Ann Surg 1987; 206:514–521.PubMedCrossRefGoogle Scholar
  15. 15.
    Foglia RP, Fonkalsrud EW, Feig SA, Moss TJ. Accuracy of diagnostic imaging as determined by delayed operative intervention for advanced neuroblastoma. J Ped Surg, 1989, in press.Google Scholar
  16. 16.
    Matthay KK, Moss TJ, Xu Z, Siegel SE, Finkelstein JZ, Seeger RC. Length of induction therapy is critical for preparing patients with advanced neuroblastoma (NBL) for bone marrow transplantation (BMT). Proc Soc Clin Oncol 1988; 7:257.Google Scholar
  17. 17.
    Moss TJ, Xu G, Rayner SA, Wells J, Reynolds CP, Heitjan D, Seeger RC. Immunohisto-logic detection of infrequent neuroblastoma (NB) cells and autologous bone marrow transplantation (BMT). Proc Am Assoc Cancer Res 1987; 28:219.Google Scholar
  18. 18.
    Graeve JLA, de Alarcon PA, Sato Y, Pringle K, Helson L. Miliary pulmonary neuroblastoma: A risk of autologous bone marrow transplantation? Cancer 1988; 62: 2125–2127.PubMedCrossRefGoogle Scholar
  19. 19.
    Glorieux, Bouffet E, Philip I, Biron P, Holzapfel L, Floret D, Bouvier R, Vitrey D, Pinkerton R, Brunat-Mentigny M, Philip T. Metastatic interstitial pneumonitis after autologous bone marrow transplantation. A consequence of reinjection of maligant cells? Cancer 1986; 58:2136–2139.Google Scholar
  20. 20.
    Medenica RD, Nava EF, Freeman AI. Diffuse pulmonary infiltration of neuroblastoma following autologous bone marrow transplantation. Blood 1985; 66:261a.Google Scholar
  21. 21.
    Philip T, Zucker JM, Bernard JL, Biron P, Kremens B, Quintana E, Gentet JC, Bordigoni P, Frappaz D, Souillet G, Philip I, Chauvin F, Favrot M. Bone marrow transplantation in an unselected group of 65 patients with stage IV neuroblastoma. In: Autologous Marrow Transplantation: Proceedings of the Third International Symposium, Dicke KA, Spitzer G, Jagannath S, eds. MD Anderson Hospital and Tumor Institute, Houston, 1987:407–417.Google Scholar
  22. 22.
    Sharkis SJ, Santos GW, Colvin M. Elimination of acute myelogenous leukemic cells from marrow and tumor suspensions in the rat with 4-hydroperoxycyclophosphamide Blood 1980; 55:521–523.PubMedGoogle Scholar
  23. 23.
    Rizzoli V, Mangoni L, Degliantoni G, Porcellini A, Carella AM, Alessandrino EP, Aglietta M, Torlontano G, Coleselli P, Mozzana A, Madon E, Resegotti L. Autologous bone marrow transplantation in acute lymphocytic leukemia. In: Autologous Marrow Transplantation: Proceedings of the Third International Symposium, Dicke KA, Spitzer G, Jagannath S, eds. MD Anderson Hospital and Tumor Institute, Houston, 1987:35–42.Google Scholar
  24. 24.
    Wada R, Seeger RC, Brodeur G, Slamon D, Rayner S, Tomayko M, Reynolds CP. Neuroblastoma cell lines that express one copy of the N-myc oncogene. Prog Clin Biol Res 1988; 271:57–59.PubMedGoogle Scholar
  25. 25.
    Yeager AM, Kaizer H, Colvin OM, Rowley SD, Braine HG, Stuart RK, Sarai R, Santos GW. Autologous bone marrow transplanation in acute nonlymphocytic leukemia using marrow treated with 4-hydroperoxycyclophosphamide. In: Autologous Marrow Transplantation: Proceedings of the Third International Symposium, Dicke KA, Spitzer G, Jagannath S, eds. MD Anderson Hospital and Tumor Institute Houston, 1987:59–68.Google Scholar
  26. 26.
    Takvorian T, Canellos GP, Ritz J, Freedman AS, Anderson kc, Mauch P, Tarbell N, Coral F, Daley H, Yeap B, Schlossman SF, Nadler LM. Prolonged disease-free survival after autologous bone marrow transplantation in patients with non-Hodgkin’s lymphoma with a poor prognosis. N Engl J Med 1987; 316:1499–1505.PubMedCrossRefGoogle Scholar
  27. 27.
    Coombes RC, Buckman R, Forrester JA, Shepherd V, O’Hare MJ, Vincent M, Powles TJ, Neville AM. In vitro and in vivo effects of a monoclonal antibody-toxin conjugate for use in autologous bone marrow transplanation for patients with breast cancer. Cancer Res 1986; 46:4217–4220.PubMedGoogle Scholar
  28. 28.
    Hartmann O, Benhamou E, Beaujean F, Kalifa C, Lejars O, Patte C, Behard C, Flamant F, Thyss A, Deville A, Vannier JP, Pautard-Muchemble B, Lemerle J. Repeated high-dose chemotherapy followed by purged autologous bone marrow transplantation as consolidation therapy in metastatic neuroblastoma. J Clin Oncol 1987; 5:1205–1211.PubMedGoogle Scholar
  29. 29.
    Macfarlane SD, Tauro GP, Rendall K, Welch JJ, Ekert H. Isolation of malignant cells from human bone marrow using a discontinuous Percoll gradient. Am J Hematol 1986; 22:403–407.PubMedCrossRefGoogle Scholar
  30. 30.
    Figdor CG, Voute PA, de Kraker J, Vernie LN, Bont WS. Physical cell separation of neuroblastoma cells from bone marrow. Prog Clin Biol Res 1985; 175:459–470.PubMedGoogle Scholar
  31. 31.
    Seeger RC, Reynolds CP, Moss TJ, Lenarsky C, Feig SA, Selch M, Ugelstad J, Wells J. Autologous bone marrow transplantation for poor prognosis neuroblastoma. In: Autologous Marrow Transplantation: Proceedings of the Third International Symposium, Dicke K, Spitzer G, Zander A, eds. MD Anderson Hospital and Tumor Institute, Houston, 1987: 375–382.Google Scholar
  32. 32.
    Anderson KC, Ritz J, Takvorian T, Coral F, Daley H, Gorgone BC, Freedman AS, Candios GP, Schlossman SF, Nadler LM. Hematologic engraftment and immune reconstitution posttransplantation with anti-B1 purged autologous bone marrow. Blood 1987; 69:597–604.PubMedGoogle Scholar
  33. 33.
    Greenberger JS, Rothstein L, DeFabritiis P, Bregni M, Bast R Jr, Ritz J, Nadler LM, Lipton JM, Sakakeeny MA. Effects of monoclonal antibody and complement treatment of human marrow on hematopoiesis in continuous bone marrow culture. Cancer Res 1985; 45:758–767.PubMedGoogle Scholar
  34. 34.
    Bast RC Jr, DeFabritiis P, Lipton J, Gelber R, Maver C, Nadler L, Sallan S, Ritz J. Elimination of malignant clonogenic cells from human bone marrow using multiple monoclonal antibodies and complement. Cancer Res 1985; 45:499–503.PubMedGoogle Scholar
  35. 35.
    Gee A, VanHilten J, Graham-Pole J, Boyle MDP. Antibody-complement mediated killing of neuroblastoma cells. Prog Clin Biol Res 1984; 175:471–483.Google Scholar
  36. 36.
    Treleaven LG, Kemshead JT. Removal of tumur cells from bone marrow: An evaluation of the available techniques. Hematol Oncol 1985; 3:65–75.PubMedCrossRefGoogle Scholar
  37. 37.
    Saarinen UM, Coccia PF, Gerson SL, Pelley R, Cheung NV. Eradication of neuroblastoma cells in vitro by monoclonal antibody and human complement: Method for purging autologous bone marrow. Cancer Res 1985; 45:5969–75.PubMedGoogle Scholar
  38. 38.
    Bregni M, DeFabritiis P, Greenberger J, Lipton J, Nadler L, Rothstein L, Ritz J, Bast RC Jr. Elimination of clonogenic tumor cells from human bone marrow using a combination of monoclonal antibody: ricin A chain conjugates. Cancer Res 1986; 46:1208–1213.PubMedGoogle Scholar
  39. 39.
    Muirhead M, Martin PJ, Torok-Storb B, Uhr JW, Vitetta ES. Use of an antibody-ricin A-chain conjugate to delete neoplastic B cells from human bone marrow. Blood 1983; 62:327–332.PubMedGoogle Scholar
  40. 40.
    Tai J, Blair AH, Ghose T. Tumour inhibition by chlorambucil covalently linked to anti-tumour globulin. Eur J Cancer 1979; 15:1357–1363.PubMedGoogle Scholar
  41. 41.
    Bernier LG, Page M, Gaudreault RC, Joly LP. A chlorambucil-anti-CEA conjugate cytotoxic for human colon adenocarcinoma cells in vitro. Br J Cancer 1984; 49:245–246.PubMedCrossRefGoogle Scholar
  42. 42.
    Embleton MJ, Rowland GF, Simmonds RG, Jacobs E, Marsden CH, Baldwin RW. Selective cytotoxicity against human tumour cells by a vindesine-monoclonal antibody conjugate. Br J Cancer 1983; 47:43–49.PubMedCrossRefGoogle Scholar
  43. 43.
    Bragman KS, Heath TD, Papahadjopoulos D. Simultaneous interaction of monoclonal antibody-targeted liposomes with two receptors on K562 cells. Biochim Biophys Acta 1983; 730:187–195.PubMedCrossRefGoogle Scholar
  44. 44.
    Favrot M, Philip I, Combaret V, Maritza O, Philip T. Experimental evaluation of an im-munomagnetic bone marrow purging procedure using the Burkitt lymphoma model. Bone Marrow Transpl 1987; 2:59–66.Google Scholar
  45. 45.
    Kemshead JT, Heath L, Gibson FM, Katz F, Richmond F, Treleaven J, Ugelstad J. Magnetic microspheres and monoclonal antibodies for the depletion of neuroblastoma cells from bone marrow: Experience, improvements and observations. Br J Cancer 1986; 54:771–778.PubMedCrossRefGoogle Scholar
  46. 46.
    Reynolds CP, Seeger RC, Vo DD, Black ST, Wells J, Ugelstad J. Model system for removing neuroblastoma cells from bone marrow using monoclonal antibodies and magnetic immunobeads. Cancer Res 1986; 46:5882–5886.PubMedGoogle Scholar
  47. 47.
    Seeger RC, Reynolds CP, Vo DD, Ugelstad J, Wells J. Depletion of neuroblastoma cells from bone marrow with monoclonal antibodies and magnetic immunobeads. Prog Clin Biol Res 1985; 175:443–458.PubMedGoogle Scholar
  48. 48.
    Treleaven JG, Gibson FM, Ugelstad J, Rembaum A, Philip T, Caine GD, Kemshead JT. Removal of neuroblastoma cells from bone marrow with monoclonal antibodies conjugated to magnetic microspheres. Lancet 1984; 1:70–73.PubMedCrossRefGoogle Scholar
  49. 49.
    Seeger RC, Moss TJ, Feig SA, Lenarsky C, Selch M, Ramsay N, Harris R, Wells J, Sather H, Reynolds CP. Bone marrow transplantation for poor prognosis neuroblastoma. Prog Clin Biol Res 1988; 271:203–213.PubMedGoogle Scholar
  50. 50.
    Gee AP, Graham-Pole J, Lee C, Bruce K, Pick T, Harvey W, Worthington-White D, Hintz M, Janssen W, Gross S. Transplantation for neuroblastoma using immunomagnetically purged autologous bone marrow. In: Autologous Marrow Transplantation: Proceedings of the Third International Symposium, Dicke KA, Spitzer G, Jagannath S, eds. MD Anderson Hospital and Tumor Institute, Houston, 1987:425–431.Google Scholar
  51. 51.
    Ades EW, Peacocke N, Sabio H. Lymphokine-activated killer cell lysis of human neuroblastoma cells: A model for purging tumor cells from bone marrow. Clin Immunol and Immunopath 1988; 46:150–156.CrossRefGoogle Scholar
  52. 52.
    Reisner Y, Kapoor N, Kirkpatrick D, Pollack M, Dupont B, Good R, O’Reilly R. Transplantation for acute leukaemia with HLA-A and B nonidentical parental marrow cells fractionated with soybean agglutinin and sheep red blood cells. Lancet 1981; 2:327–331.PubMedCrossRefGoogle Scholar
  53. 53.
    Elkins WL. Preliminary studies of lectin agglutination of metastatic neuroblastoma. Prog Clin Biol Res 1984; 175:405–411.Google Scholar
  54. 54.
    De Fabritiis P, Bregni M, Lipton J, Greenberger J, Nadler L, Rothstein L, Korbling M, Ritz J, Bast RC Jr. Elimination of clonogenic Burkitt’s lymphoma cells from human bone marrow using 4-hydroperoxycyclophosphamide in combination with monoclonal antibodies and complement. Blood 1985; 65:1064–1070.PubMedGoogle Scholar
  55. 55.
    Jones RJ, Zuehlsdorf M, Rowley SD, Hilton J, Santos GW, Sensenbrenner LL, Colvin OM. Variability in 4-hydroperoxycyclophosphamide activity during clinical pruging for autologous bone marrow transplantation. Blood 1987; 70:1490–1494.PubMedGoogle Scholar
  56. 56.
    Kaizer H, Stuart RK, Brookmeyer R, Beschorner WE, Braine HG, Burns WH, et al. Autologous bone marrow transplantation in acute leukemia: A phase I study of in vitro treatment of marrow with 4-hydroperoxycyclophosphamide to purge tumor cells. Blood 1985; 65:1504–1510.PubMedGoogle Scholar
  57. 57.
    Bruchelt G, Buck J, Girgert R, Treuner J, Niethammer D. The role of reactive oxygen compounds derived from 6-hydroxydopamine for bone marrow purging from neuroblastoma cells. Biochim Biophys Res Comm 1985; 130:168–174.CrossRefGoogle Scholar
  58. 58.
    Helson L, Clarkson B, Langleben A, Helson C, O’Reilly RD, Gulati S. Purging neuroblastoma cells from human bone marrow. Eur J Cancer 1982; 18(10): 1043.Google Scholar
  59. 59.
    Reynolds CP, Perez-Polo JR. Ascorbic acid enhances the cytotoxic effect of 6-hydroxydopamine for human neuroblastoma cell lines. Neurosci Lett 1981; 26:151–155.PubMedCrossRefGoogle Scholar
  60. 60.
    Reynolds GP, Reynolds DA, Frenkel EP, Smith RG. Selective toxicity of 6-hydroxydopamine and ascorbate for human neuroblastoma in vitro: A model for clearing marrow prior to autologous transplant. Cancer Res 1982; 42:1331–1336.PubMedGoogle Scholar
  61. 61.
    Pinkerton CR, Philip T, Biron P, Frapazz D, Phillipe N, Zucker JM, Bernard JL, Philip I, Kemshead J, Favrot M. High-dose melphalan, vincristine, and total-body irradiation with autologous bone marrow transplantation in children with relapsed neuroblastoms: A phase II study. Med Ped Oncol 1987; 15:236–240.Google Scholar
  62. 62.
    Sieber F, Rao S, Rowley SD, Sieber-Blum M. Dye-mediated photolysis of human neuroblastoma cells: Implications for autologous bone marrow transplantation. Blood 1986; 68:32–36.PubMedGoogle Scholar
  63. 63.
    Sieber F, Sieber-Blum M. Dye-mediated photosensitization of murine neuroblastoma cells. Cancer Res 1986; 46:2072–2076.PubMedGoogle Scholar
  64. 64.
    Aptzpodien J, Gulati SC, Strife A, Clarkson BD. Photoradiation models for the clinical ex vivo treatment of autologous bone marrow grafts. Blood 1987; 70:484–489.Google Scholar
  65. 65.
    Dulley FL, Kanfer EJ, Appelbaum FR, Amos D, Hill RS, Buckner CD, Shulman HM, McDonald GB, Thomas ED. Venoocclusive disease of the liver after chemoradiotherapy and autologous bone marrow transplantation. Transplantation 1987; 43:870–873.PubMedGoogle Scholar
  66. 66.
    Shulman HM, McDonald GB, Matthews D, Doney KC, Kopecky KJ, Gauvreau JM, Thomas ED. An analysis of hepatic venoocclusive disease and centrilobular hepatic degeneration following bone marrow transplantation. Gastroenterology 1980; 79:1178–1191.PubMedGoogle Scholar
  67. 67.
    Murray JA, LaBrecque DR, Gingrich RD, Pringle KC, Mitros FA. Successful treatment of hepatic venocclusive disease in bone marrow transplant patient with side-to-side portacaval shunt. Gastroenterology 1987; 92:1073–1077.PubMedGoogle Scholar
  68. 68.
    Valteau D, Hartmann O, Benhamou E, Caillaud JM, Brugieres L, Beaujean F, Patte C, Flamant F, Leerle J. Nonbacterial nonfungal interstitial pneumonitis following autologous bone marrow transplantation in children treated with high-dose chemotherapy without total-body irradiation. Transplantation 1988; 45:737–740.PubMedCrossRefGoogle Scholar
  69. 69.
    Pritchard J, McElwain TJ, Graham-Pole J. Treatment of advanced neuroblastoma with supralethal chemotherapy, radiation, and allogeneic or autologous marrow reconstitution. Br J Cancer 1982; 45:86–94.PubMedCrossRefGoogle Scholar
  70. 70.
    Hartmann O, Kalifa C, Benhamou E, Patte C, Flamant F, Jullien C, Beaujean F, Lemerle. Treatment of advanced neuroblastoma with high-dose melphalan and autologous bone marrow transplantation. Cancer Chemother Pharmacol 1986; 16:165–169.PubMedCrossRefGoogle Scholar
  71. 71.
    Pinkerton R, Pritchard J, deKraker J, Jones D, Germond S, Love S. ENSG 1-randomized study of high-dose melphalan in neuroblastoma. In: Autologous Marrow Transplantation: Proceedings of the Third International Symposium, Dicke KA, Spitzer G, Jagannath S, ed. MD Anderson Hospital and Tumor Institute, Houston, 1987:401–405.Google Scholar
  72. 72.
    Seeger RC, Reynolds CP, Moss TJ, Lenarsky C, Feig SA, Selch M, Ugelstad J, Wells J. Autologous bone marrow transplantation for poor-prognosis neuroblastoma. In: Autologous Marrow Transplantation: Proceedings of the Third International Symposium, Dicke KA, Spitzer G, Jagannath S, eds. MD Anderson Hospital and Tumor Institute, Houston, 1987:375–382.Google Scholar
  73. 73.
    August CS, Serota FT, Koch PA, Burkey E, Schlesinger H, Elkins WL, Evans AE, D’Angio GJ. Treatment of advanced neuroblastoma with supralethal chemotherapy, radiation, and allogeneic or autologous marrow reconstitution. J Clin Oncol 1984; 2:609–616.PubMedGoogle Scholar
  74. 74.
    August CS, Bayever E, Levy Y, et al. Eight years’ experience in neuroblastoma patients transplanted after relapse. Proc Am Assoc Cancer Res 1986; 27:203.Google Scholar
  75. 75.
    Evans AE. Melphalan therapy for children with metastatic neuroblastoma. Cancer Treat Rep 1958; 52:293–296.Google Scholar
  76. 76.
    Hartmann O, Benhamou E, Beaujean F, Pico JL, Kalifa C, Flamant F, Lemerle J. High-dose busulfan and cyclophosphamide with autologous bone marrow transplantation support in advanced malignancies in children: A phase II study. J Clin Oncol 1986; 4:1804–1810.PubMedGoogle Scholar
  77. 77.
    Stein J, Strandjord S, Saarinen U, Warkentin P, Gerson S, Lazarus H, Von Hoff D, Coccia P, Cheung N-K. In vitro treatment of autologous bone marrow for neuroblastoma patients with anti GD2 monoclonal antibody and human complement: A pilot study. Prog Clin Biol Res 1988; 271:237–248.PubMedGoogle Scholar
  78. 78.
    Lazarus HM, Reed MD, Spitzer TR, Rabaa S, Blumer JL, High-dose iv thiotepa and cryopreserved autologous bone marrow transplantation for therapy of refractory cancer. Cancer Treat Rep 1987; 71:689–695.PubMedGoogle Scholar
  79. 79.
    Hayes FA, Thompson EI, Parvey L, Rao B, Kun L, Parham D, Hustu HO. Metastatic Ewing’s sarcoma: Remission induction and survival. J Clin Oncol 1987; 5:1199–1204.PubMedGoogle Scholar
  80. 80.
    Pinkerton R, Philip T, Bouffet E, Lashford L, Kemshead J. Autologous bone marrow transplantation in paediatric solid tumours. Clin Hematol 1986; 15:187–203.Google Scholar
  81. 81.
    Graham-Pole J, Lazarus HM, Herzig RH, Gross S, Coccia P, Weiner R, Strandjord S. High-dose melphalan therapy for treatment of children with refractory neuroblastoma and Ewing’s sarcoma. Am J Ped Hematol/Oncol 1984; 6:17–26.Google Scholar
  82. 82.
    Cornbleet MA, Corringham RET, Prentice HG, Boesen EM, McElwain TJ. Treatment of Ewing’s sarcoma with high-dose melphalan and autologous bone marrow transplantation. Cancer Treat Rep 1981; 65:241–244.PubMedGoogle Scholar
  83. 83.
    Miser J. Personal Communication.Google Scholar
  84. 84.
    Houghton JA, Cook RL, Pamela JL, Houghton PJ, Melphalan: A potential new agent in the treatment of childhood rhabdomyosarcoma. Cancer Treat Rep 1985; 69:91–96.PubMedGoogle Scholar
  85. 85.
    Hara T, Miyazaki S, Ishii E, Yoshida N, Inaba K, Ikeda K, Goya N. High-dose l-(amino-2-methyl-5-pyrimidinyl)-methyl-3-(2-chloroethyl)-3-ntirosurea hydrochloride (ACNU) with autologous bone marrow rescue for patients with brain stem gliomas. Child’s Brain 1984; 11:369–374.PubMedGoogle Scholar
  86. 86.
    Hildebrand J, Badjou R, Collard-Ronge E, Delforge A, Malarme M, Spiro T, Sztern B, Vandensteene A, Stryckmans PA. Treatment of brain gliomas with high does of CCNU and autologous bone marrow transplantation. Biomed 1980; 32:71–75.Google Scholar
  87. 87.
    Wolff SN, Phillips GL, Herzig GP. High-dose carmustine with autologous bone marrow transplantation for the adjuvant treatment of high-grade gliomas of the central nervous system. Cancer Treat Rep 1987; 71:183–185.PubMedGoogle Scholar
  88. 88.
    Giannone L, Wolff SN. Phase II treatment of central nervous system gliomas with high-dose etoposide and autologous bone marrow transplantation. Cancer Treat Rep 1987; 71:759–761.PubMedGoogle Scholar
  89. 89.
    Baumgartner C, Bleher EA, Brun del Re G, Bucher U, Deubelbeiss KA, Greiner R, Hirt A, Imbach P, Luthy A, Odavic R, Wagner HP. Autologous bone marrow transplantation in the treatment of children and adolescents with advanced malignant tumors. Med Ped Oncol 1984; 104–111.Google Scholar
  90. 90.
    Ekert H, Tiedemann K, Waters KD, Ellis WM. Experience with high dose multiagent chemotherapy and autologous bone marrow rescue in the treatment of twenty-two children with advanced tumours. Aust Paed J 1984; 20:195–201.Google Scholar
  91. 91.
    Saleh RA, Gross A, Cassano W, Gee A. Metastatic retinoblastoma successfully treated with immunomagnetic purged autologous bone marrow transplantation. Cancer 1988; 62:2301–2303.PubMedCrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1995

Authors and Affiliations

  • Thomas J. Moss

There are no affiliations available

Personalised recommendations